.png)
EMA starts review of Paxlovid for treating patients with COVID-19 - EMA starts review of Paxlovid for treating patients with COVID-19
EMA starts review of Paxlovid for treating patients with COVID-19
EMA is reviewing currently available data on the use of Paxlovid (PF-07321332/ritonavir), an oral treatment for COVID-19 developed by Pfizer. EMA is starting this review to support national authorities who may decide on its early use for COVID-19, for example in emergency use settings, prior to marketing authorisation.
Published on: 19 November 2021